Scholarlink

<p>Accurate assessment of performance status (PS) in oncology care is crucial for improving clinical decisions, therapy selection and anticipated risks of treatment toxicity. While physical function is traditionally assessed in the clinic, in-clinic instruments do not capture the full spectrum of daily functioning. Digital health technologies (DHTs) can address this limitation by passively monitoring patients in their daily environment. Our study showed at-home physical activity and gait metrics from DHTs were associated with self-reported PS in participants with cancer, and these metrics had greater discriminatory power than in-clinic measures among this cohort. The DHT-derived metrics were also significantly correlated with patient-reported-outcomes, and used of the devices was broadly acceptable to study participants. Therefore, integrating DHTs into oncological practice could significantly refine how PS is measured and utilized, ultimately enhancing treatment decision-making and clinical outcomes. (ClinicalTrials.gov NCT03952767).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Improved functional assessment in cancer patients using home-based digital technologies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月21日

查看全文
  • F. Isik Karahanoglu,
  • Christopher E. Jensen,
  • Xuemei Cai,
  • Mar Santamaria,
  • Dimitrios Psaltos,
  • Andrew Messere,
  • Charmaine Demanuele,
  • Jodi Stone,
  • Anil Tarachandani,
  • Lukas Adamowicz,
  • Hyman Muss,
  • William A. Wood

摘要

Accurate assessment of performance status (PS) in oncology care is crucial for improving clinical decisions, therapy selection and anticipated risks of treatment toxicity. While physical function is traditionally assessed in the clinic, in-clinic instruments do not capture the full spectrum of daily functioning. Digital health technologies (DHTs) can address this limitation by passively monitoring patients in their daily environment. Our study showed at-home physical activity and gait metrics from DHTs were associated with self-reported PS in participants with cancer, and these metrics had greater discriminatory power than in-clinic measures among this cohort. The DHT-derived metrics were also significantly correlated with patient-reported-outcomes, and used of the devices was broadly acceptable to study participants. Therefore, integrating DHTs into oncological practice could significantly refine how PS is measured and utilized, ultimately enhancing treatment decision-making and clinical outcomes. (ClinicalTrials.gov NCT03952767).